Navigation Links
New England Biolabs opens seventh subsidiary in Singapore
Date:3/21/2013

IPSWICH, Mass., March 21, 2013 /PRNewswire/ -- New England Biolabs (NEB), a world leader in the production of reagents for the life science industry, extended its global subsidiary network with the opening of New England Biolabs Pte. Ltd., in Singapore.

(Logo:  http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b )

"The Singapore facility will provide the vibrant local scientific research community with more efficient access to the latest NEB products, technical support in the local time zone and languages, as well as OEM partnership opportunities," says Sue Yap , General Manager for the Singapore office.

Singapore, recently cited by Scientific American as the world's third most innovative country in biotech, is home to more than 5,000 life science researchers, numerous start-ups, and facilities for many of the largest pharmaceutical companies. Its significance to the biological sciences was reflected this past January, when the country hosted the inaugural Global Young Scientists Summit, featuring 12 Nobel Prize Laureates. Among these was the Chief Scientific Officer of NEB, Sir Richard Roberts , who conducted a seminar to inaugurate the opening of the NEB office.

"Singapore has a world class reputation in the life sciences. This new office will allow us to offer even greater personalized service and, when appropriate, to explore higher levels of collaboration, especially with the startup biotech companies now multiplying in Singapore," says Roberts.

NEB also maintains subsidiary offices in Canada, China, France, Germany, Japan, and the United Kingdom.

For more information, send e-mail to sales.sg@neb.com or telephone +65 67760903.

About New England Biolabs

Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, library preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and seven subsidiaries located in Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs visit www.neb.com.


'/>"/>
SOURCE New England Biolabs
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
2. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
3. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
4. New England Biolabs Demonstrates Support for Interactive Scientific Literature by Collaborating with AQnowledge
5. New England Biolabs Develops Novel Polymerase with Ultra-High Fidelity and Minimal GC Bias
6. New England Cord Blood Bank chooses Sepax 2 from Biosafe as their Cord Blood Processing Platform
7. NIH Awards New England Biolabs a Phase II SBIR Grant for the Research and Development of Novel Enzymes for Epigenetic Studies
8. New England Biolabs New Website Adds Technical Information, Easy Ordering, and Better Search
9. Store-A-Tooth™ Stem Cell Banking Announces Appointment of Dedicated Sales Representative in New England
10. Quadrant Engineering Plastic Products Appoints a New England Territorial Manager and Production Supervisor
11. First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
Breaking Biology Technology:
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
Breaking Biology News(10 mins):